Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10877
Title: Evaluation of clinical, epidemiological and hemodynamic data of our patients with pulmonary hypertension
Authors: Gürses, Dolunay
Gül, Ö.
Keywords: Eisenmenger syndrome
Pulmonary hypertension
Treatment
bosentan
angiography
Article
atrioventricular septal defect
child
chronic lung disease
clinical article
clinical evaluation
congenital heart disease
echocardiography
Eisenmenger complex
electrocardiogram
epidemiological data
female
follow up
hemodynamics
human
male
monotherapy
pulmonary hypertension
quality of life
retrospective study
six minute walk test
Publisher: Galenos Yayincilik,
Abstract: INTRODUCTION: This study was conducted to determine the epidemiological characteristics, quality of life, treatment modalities and efficacy of our treatment in patients with pulmonary arterial hypertension (PAH). METHODS: Fifteen patients (11 girls, 4 boys) who were followed up for PAH in the Department of Pediatric Cardiology between January 2008 and December 2016 were evaluated retrospectively. RESULTS: The mean age of patients at first admission was 10.7±5 (3-20) years. Only one of the patients (7%) had primary PAH, and two patients (13%) had PAH associated with chronic lung disease. Twelve patients (80%) had PAH secondary to congenital heart disease. Of these patients, 10 had Eisenmenger syndrome and two were operated for congenital heart disease with a left to right shunt. Six patients (60%) had VSD, and two (20%) had atrioventricular septal defect in 10 patients with Eisenmenger syndrome. The most common symptom was easy fatigue (83%). All of the patients had telecardiography, electrocardiogram and echocardiography, and 87% of patients underwent six minute walking test and angiography. All patients undergoing angiography were tested for vasoreactivity and all were negative. When the treatments at the last controls of the patients are evaluated; 53.3% of the patients received monotherapy, 46.7% received combination therapy. The most frequently started monotherapy was bosentan (46.7%). Four patients were died during follow-up. DISCUSSION and CONCLUSION: Pulmonary arterial hypertension is a chronic progressive disease that can be caused by many etiologic factors. If not treated; progressive increase in pulmonary vascular resistance leads to right ventricular failure and premature death. Accumulating PAH patients in experienced centers will ensure appropriate diagnosis, follow-up and treatment options. © 2018, Galenos Yayincilik. All rights reserved.
URI: https://hdl.handle.net/11499/10877
ISSN: 1304-9054
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

Page view(s)

44
checked on Aug 24, 2024

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.